NCT02484430 - Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

December 28, 2018

Study Completion Date

March 5, 2024

Conditions

B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaT Acute Lymphoblastic Leukemia

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sapanisertib

Given PO

Trial Locations (14)

20007

MedStar Georgetown University Hospital, Washington D.C.

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic in Rochester, Rochester

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Clinical Research Center, Fairway

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH